Longevity

Anti-ageing, mitochondria and healthy ageing claims. Ranked by evidence grade, then user score. Each grade is for the use named on the card, which may not be this goal.

• Sleep
• Recovery & injury
• Fat loss
• Cognition & mood
• Libido & sexual health
• Longevity
• Skin & hair
• Immune
• Muscle & strength

Evidence grade Any grade A only B or better C or better D or better US FDA Any status Approved for this useApproved for another use onlyNot approved WADA (sport) Any status Not prohibitedProhibited or likely prohibitedNot named / unclear

11 of 11 peptides shown

1. C

   1.Elamipretide

   Preliminary human data · for mitochondrial support / anti-ageing in people without Barth syndrome

   FDA Approved for Barth syndrome only WADA Not named
   User score 3.5
   Outcomes: Positive 11 of 21 (52%), Mixed 6 of 21 (29%), Negative 1 of 21 (5%), No effect 2 of 21 (10%), Unclear 1 of 21 (5%)
   Men 45–60: 0 · everyone: 21 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; page tags mentions it; summary mentions it.

2. C

   2.GHK-Cu

   Preliminary human data · for topical skin and hair cosmetic use (injectable 'systemic anti-ageing' has no human trials)

   FDA Not approved WADA Not named
   User score 3.5
   Outcomes: Positive 44 of 64 (69%), Mixed 5 of 64 (8%), Negative 4 of 64 (6%), No effect 4 of 64 (6%), Unclear 7 of 64 (11%)
   Men 45–60: 1 · everyone: 64 reports · approximate

   Why it’s listed: graded use mentions it.

3. C

   3.Khavinson bioregulators

   Preliminary human data · for general anti-ageing / organ 'bioregulation' (the family as a class)

   FDA Varies by substance WADA Varies by substance
   User score 3.0
   Outcomes: Positive 10 of 18 (56%), Mixed 1 of 18 (6%), Negative 1 of 18 (6%), No effect 3 of 18 (17%), Unclear 3 of 18 (17%)
   Men 45–60: 0 · everyone: 18 reports · approximate

   Why it’s listed: graded use mentions it.

4. C

   4.Nicotinamide adenine dinucleotide, oxidized form

   Preliminary human data · for NAD+ infusions/injections for energy, cognition and anti-ageing

   FDA Not approved WADA Not named
   User score 2.5
   Outcomes: Positive 11 of 30 (37%), Mixed 6 of 30 (20%), Negative 8 of 30 (27%), No effect 1 of 30 (3%), Unclear 4 of 30 (13%)
   Men 45–60: 1 · everyone: 30 reports · approximate

   Why it’s listed: graded use mentions it; page tags mentions it.

5. C

   5.Epitalon

   Preliminary human data · for longevity, telomeres and sleep

   FDA Not approved WADA Likely prohibited (S0)
   User scoretoo few reports (8)
   Men 45–60: 0 · everyone: 8 reports · approximate

   Why it’s listed: graded use mentions it.

6. C

   6.Rapamycin

   Preliminary human data · for longevity / healthy ageing (off-label, low intermittent dosing)

   FDA Approved for transplant & LAM only WADA Not named
   User scoretoo few reports (9)
   Men 45–60: 0 · everyone: 9 reports · approximate

   Why it’s listed: graded use mentions it.

7. C

   7.SNAP-8

   Preliminary human data · for topical anti-wrinkle

   FDA Not approved WADA Not named
   User scoretoo few reports (8)
   Men 45–60: 0 · everyone: 8 reports · approximate

   Why it’s listed: summary mentions it.

8. C

   8.Thymalin

   Preliminary human data · for immune 'rejuvenation', thymus regeneration and longevity

   FDA Not approved WADA Not named
   User scoretoo few reports (5)
   Men 45–60: 0 · everyone: 5 reports · approximate

   Why it’s listed: graded use mentions it.

9. D

   9.MOTS-c

   Preclinical only · for metabolism, exercise performance and longevity

   FDA Not approved WADA Prohibited (S4.4.1)
   User score 2.5
   Outcomes: Positive 10 of 25 (40%), Mixed 7 of 25 (28%), Negative 4 of 25 (16%), No effect 3 of 25 (12%), Unclear 2 of 25 (8%)
   Men 45–60: 2 · everyone: 25 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; summary mentions it.

10. D

    10.FOXO4-DRI

    Preclinical only · for senolytic anti-ageing

    FDA Not approved WADA Likely prohibited (S0)
    User score 1.0
    Outcomes: Positive 2 of 11 (18%), Mixed 1 of 11 (9%), Negative 2 of 11 (18%), No effect 2 of 11 (18%), Unclear 4 of 11 (36%)
    Men 45–60: 0 · everyone: 11 reports · approximate

    Why it’s listed: graded use mentions it; substance class mentions it.

11. D

    11.Humanin

    Preclinical only · for longevity, metabolic and neuroprotective use

    FDA Not approved WADA Likely prohibited (S0)
    User scoretoo few reports (7)
    Men 45–60: 0 · everyone: 7 reports · approximate

    Why it’s listed: graded use mentions it; substance class mentions it; page tags mentions it; summary mentions it.

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.